<DOC>
	<DOCNO>NCT00509210</DOCNO>
	<brief_summary>The purpose study assess safety pharmacokinetics Telaprevir follow administration multiple oral dos subject moderate severe hepatic impairment .</brief_summary>
	<brief_title>Study Telaprevir Subjects With Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Clinically diagnose Child Pugh score 79 great 10 Women nonchildbearing age Tested positive HIV , Hepatitis C , Hepatitis B</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Liver Disease</keyword>
</DOC>